{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:08:17Z","timestamp":1789992497332,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,5,27]],"date-time":"2011-05-27T00:00:00Z","timestamp":1306454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s10549-011-1601-4","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T11:32:29Z","timestamp":1306409549000},"page":"635-643","source":"Crossref","is-referenced-by-count":52,"title":["PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression"],"prefix":"10.1007","volume":"129","author":[{"given":"Kevin","family":"Kalinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Heguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umeshkumar K.","family":"Bhanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Moynahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,27]]},"reference":[{"issue":"8","key":"1601_CR1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev 7(8):606\u2013619","journal-title":"Nat Rev"},{"issue":"41","key":"1601_CR2","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497\u20135510. doi: 10.1038\/onc.2008.245","journal-title":"Oncogene"},{"issue":"22","key":"1601_CR3","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.1073\/pnas.0907011107","volume":"107","author":"S Loi","year":"2010","unstructured":"Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107(22):10208\u201310213. doi: 10.1073\/pnas.0907011107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"1601_CR4","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","volume":"15","author":"K Kalinsky","year":"2009","unstructured":"Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16):5049\u20135059. doi: 10.1158\/1078-0432.CCR-09-0632","journal-title":"Clin Cancer Res"},{"issue":"38","key":"1601_CR5","doi-asserted-by":"crossref","first-page":"38ra47","DOI":"10.1126\/scitranslmed.3000611","volume":"2","author":"HG Russnes","year":"2010","unstructured":"Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, Sorlie T, Borgen E, Rye IH, Langerod A, Chin SF, Teschendorff AE, Stephens PJ, Maner S, Schlichting E, Baumbusch LO, Karesen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Borresen-Dale AL (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2(38):38ra47. doi: 10.1126\/scitranslmed.3000611","journal-title":"Sci Transl Med"},{"issue":"12","key":"1601_CR6","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdp234","volume":"20","author":"M Arnedos","year":"2009","unstructured":"Arnedos M, Nerurkar A, Osin P, A\u2019Hern R, Smith IE, Dowsett M (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20(12):1948\u20131952. doi: 10.1093\/annonc\/mdp234","journal-title":"Ann Oncol"},{"issue":"1","key":"1601_CR7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.bjc.6602256","volume":"92","author":"RJ Burcombe","year":"2005","unstructured":"Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92(1):147\u2013155. doi: 10.1038\/sj.bjc.6602256","journal-title":"Br J Cancer"},{"issue":"1","key":"1601_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1677\/erc.0.0100091","volume":"10","author":"S Taucher","year":"2003","unstructured":"Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlbock M, Jakesz R (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10(1):91\u201398","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1601_CR9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/B:BREA.0000004378.15859.51","volume":"82","author":"S Taucher","year":"2003","unstructured":"Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger GG, Mittlbock M, Jakesz R (2003) Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2\/neu in patients with breast cancer. Breast Cancer Res Treat 82(3):207\u2013213. doi: 10.1023\/B:BREA.0000004378.15859.51","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1601_CR10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1309\/AJCP09VUTZWZXBMJ","volume":"131","author":"M Brunelli","year":"2009","unstructured":"Brunelli M, Manfrin E, Martignoni G, Miller K, Remo A, Reghellin D, Bersani S, Gobbo S, Eccher A, Chilosi M, Bonetti F (2009) Genotypic intratumoral heterogeneity in breast carcinoma with HER2\/neu amplification: evaluation according to ASCO\/CAP criteria. Am J Clin Pathol 131(5):678\u2013682. doi: 10.1309\/AJCP09VUTZWZXBMJ","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"1601_CR11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1078-0432.CCR-06-1304","volume":"13","author":"LN Harris","year":"2007","unstructured":"Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13(4):1198\u20131207. doi: 10.1158\/1078-0432.CCR-06-1304","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1601_CR12","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1200\/JCO.2005.02.8886","volume":"24","author":"J Hurley","year":"2006","unstructured":"Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24(12):1831\u20131838. doi: 10.1200\/JCO.2005.02.8886","journal-title":"J Clin Oncol"},{"issue":"23","key":"1601_CR13","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","volume":"15","author":"EA Mittendorf","year":"2009","unstructured":"Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381\u20137388. doi: 10.1158\/1078-0432.CCR-09-1735","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1601_CR14","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2009.26.7245","volume":"28","author":"WT Barry","year":"2010","unstructured":"Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB (2010) Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 28(13):2198\u20132206. doi: 10.1200\/JCO.2009.26.7245","journal-title":"J Clin Oncol"},{"issue":"9","key":"1601_CR15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198809013190901","volume":"319","author":"B Vogelstein","year":"1988","unstructured":"Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525\u2013532. doi: 10.1056\/NEJM198809013190901","journal-title":"N Engl J Med"},{"issue":"2","key":"1601_CR16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-009-0406-1","volume":"120","author":"J Dunlap","year":"2010","unstructured":"Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120(2):409\u2013418. doi: 10.1007\/s10549-009-0406-1","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1601_CR17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yexmp.2009.09.016","volume":"88","author":"H Li","year":"2010","unstructured":"Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H, Zhu H (2010) PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 88(1):150\u2013155. doi: 10.1016\/j.yexmp.2009.09.016","journal-title":"Exp Mol Pathol"},{"issue":"14","key":"1601_CR18","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1158\/0008-5472.CAN-08-2660","volume":"70","author":"A Miron","year":"2010","unstructured":"Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K (2010) PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70(14):5674\u20135678. doi: 10.1158\/0008-5472.CAN-08-2660","journal-title":"Cancer Res"},{"issue":"4","key":"1601_CR19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1078-0432.CCR-10-1133","volume":"17","author":"J Dupont Jensen","year":"2011","unstructured":"Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Gardner H (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17(4):667\u2013677. doi: 10.1158\/1078-0432.CCR-10-1133","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1601_CR20","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","volume":"70","author":"M Janakiraman","year":"2010","unstructured":"Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB (2010) Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70(14):5901\u20135911. doi: 10.1158\/0008-5472.CAN-10-0192","journal-title":"Cancer Res"},{"issue":"33","key":"1601_CR21","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.1073\/pnas.0705218104","volume":"104","author":"C Hafner","year":"2007","unstructured":"Hafner C, Lopez-Knowles E, Luis NM, Toll A, Baselga E, Fernandez-Casado A, Hernandez S, Ribe A, Mentzel T, Stoehr R, Hofstaedter F, Landthaler M, Vogt T, Pujol RM, Hartmann A, Real FX (2007) Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 104(33):13450\u201313454. doi: 10.1073\/pnas.0705218104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1601_CR22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/1078-0432.CCR-10-1369","volume":"17","author":"K Graham","year":"2011","unstructured":"Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL (2011) Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 17(2):236\u2013246. doi: 10.1158\/1078-0432.CCR-10-1369","journal-title":"Clin Cancer Res"},{"issue":"2 Pt 1","key":"1601_CR23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-06-0267","volume":"13","author":"N Maruyama","year":"2007","unstructured":"Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13(2 Pt 1):408\u2013414","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1601_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-009-0504-0","volume":"118","author":"CM Heaphy","year":"2009","unstructured":"Heaphy CM, Griffith JK, Bisoffi M (2009) Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 118(2):229\u2013239. doi: 10.1007\/s10549-009-0504-0","journal-title":"Breast Cancer Res Treat"},{"issue":"75","key":"1601_CR25","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26. doi: 10.1126\/scitranslmed.3002003","journal-title":"Sci Transl Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1601-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1601-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1601-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:33:48Z","timestamp":1559234028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1601-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,27]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1601-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,27]]}}}